Medscape Asks: Does Therapy Boost Ketamine's Benefits?

Medscape Revisits an Old Question: Is Therapy the Missing Piece?

On August 31, 2026, Medscape, a widely read clinician-facing medical news publication, published a piece titled "Ketamine and Psychotherapy: A Winning Combination?" The syndicated headline and summary do not include the full article body or specific study data, so this analysis focuses on what the question itself signals for patients and providers rather than claiming to report the outlet's underlying findings in detail. Readers who want the full clinical detail should read the original Medscape article directly.

The framing matters because it reflects a debate that has been building across the ketamine treatment field for several years: should ketamine be delivered as a standalone medical infusion or nasal spray session, or should it be paired with structured talk therapy before, during, or after dosing? This second model is generally called ketamine-assisted psychotherapy, or KAP, a treatment approach in which a licensed therapist works with a patient in the same session as, or in close coordination with, ketamine administration, with the goal of helping the patient process the psychological material that can surface during and after the dissociative experience.

Medscape's audience is primarily clinicians, so a headline posed as a question, "a winning combination?", typically signals that the outlet is examining evidence, expert opinion, or clinical debate rather than declaring a settled conclusion. That framing is consistent with how the ketamine-for-depression field has evolved: the FDA-approved esketamine nasal spray (brand name Spravato) is authorized specifically for use in conjunction with an oral antidepressant and under clinical monitoring, while off-label intravenous or intramuscular ketamine for mood disorders is administered under a wider range of protocols, some of which include structured psychotherapy and some of which do not.

What This Means for Telehealth Ketamine Patients

The KAP-versus-medical-model debate is directly relevant to anyone evaluating an online or telehealth ketamine program, because the two approaches differ in cost, session structure, and the kind of support available if difficult emotions or memories surface during treatment. According to the National Institute of Mental Health, ketamine can produce dissociative effects and rapid shifts in mood and perception, which is part of why medical supervision during dosing is standard practice regardless of whether formal psychotherapy is included.

Programs that build psychotherapy into the treatment plan generally involve a licensed mental health clinician, not just a prescribing physician or nurse practitioner, who conducts preparation sessions before dosing and integration sessions afterward to help the patient make sense of the experience. Programs built on a purely medical model may focus on symptom monitoring and dosing safety without a parallel therapy track. Neither model is inherently superior for every patient, and the Medscape headline's question-mark framing suggests the clinical evidence is still being actively debated rather than conclusively resolved in either direction.

For telehealth specifically, this distinction can matter more than it does in an in-person clinic. Remote ketamine programs vary widely in whether a therapist is involved at all, whether that therapist is licensed in the patient's state, and whether integration support happens in real time or is left to the patient to arrange separately. A patient choosing a telehealth ketamine provider should treat "do you include psychotherapy, and is it with a licensed therapist" as a standard screening question, the same way they would ask about medical monitoring during dosing or emergency protocols.

Practical Steps for Readers Evaluating a Program

Before starting treatment, ask any prospective provider whether psychotherapy is offered as part of the program or only as a referral, and whether the therapist involved is licensed to practice in your state, an important detail for telehealth, since licensure is typically state-specific. Ask how preparation and integration sessions are structured, since these are the sessions most closely tied to processing what comes up during dosing. Ask what happens if you have a difficult emotional reaction during or after a session, and who you can reach out to. Finally, ask about total cost, since programs that bundle therapist time with medical dosing are often priced differently than infusion-only models, and that difference should be clear before you commit to a treatment course.

None of this requires assuming one model is safer or more effective than the other. It requires asking your provider to be specific about what you're actually getting, since "ketamine treatment" can describe meaningfully different care experiences depending on whether structured therapy is part of the plan.